<html>
<head>
<title>Utah Legislature HB0308</title>
</head>
<body>
<div id="content">
<font face="Arial">
</font><font face="Arial" size="3">1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center><b>DISEASE PREVENTION AND SUBSTANCE ABUSE</b></center><br/>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><center>REDUCTION AMENDMENTS</b></font><font face="Arial" size="2"></center><br/>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center>2016 GENERAL SESSION</center><br/>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center>STATE OF UTAH</center><br/>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center></font><font face="Arial" size="3"><b>Chief Sponsor:  Steve Eliason</b></font><font face="Arial" size="2"></center><br/>6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center></font><font face="Arial" size="3">Senate Sponsor: </font><font face="Arial" size="2"></font><font face="Arial" size="3">  Brian E. Shiozawa</font><font face="Arial" size="2"></center><br/>7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <hr style="width:90%; padding: 0; border: none; border-top: thick double #333; color: #333; text-align: right" /><br/>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>LONG TITLE</b><br/>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>General Description:</b><br/>10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This bill amends the Utah Health Code.<br/>11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Highlighted Provisions:</b><br/>12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This bill:<br/>13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;authorizes the operation of syringe exchange programs in the state;<br/>14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;specifies the requirements a syringe exchange program must meet;<br/>15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requires the department to report to the Legislature every two years on the activities<br/>16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and outcomes of syringe programs operating in the state; and<br/>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requires rulemaking by the department.<br/>18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Money Appropriated in this Bill:</b><br/>19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None<br/>20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Special Clauses:</b><br/>21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None<br/>22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Utah Code Sections Affected:</b><br/>23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ENACTS:<br/>24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#26-7-8">26-7-8</a></b>, Utah Code Annotated 1953<br/>25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <hr style="width:90%; padding: 0; border: none; border-top: thick double #333; color: #333; text-align: right" /><br/>26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Be it enacted by the Legislature of the state of Utah:</i><br/>27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.  Section <b>26-7-8</b><a name="26-7-8"></a> is enacted to read:<br/><hr>28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26-7-8.</u></b>  <b>Syringe exchange and education.</b><br/>29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  The following may operate a syringe exchange program in the state to prevent the</u><br/>30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>transmission of disease and reduce morbidity and mortality among individuals who inject</u><br/>31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>drugs, and those individuals' contacts:</u><br/>32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  a government entity, including:</u><br/>33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  the department;</u><br/>34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  a local health department, as defined in Section <a href="http://le.utah.gov/UtahCode/SectionLookup.jsp?section=26a-1-102&session=2016GS">26A-1-102</a>;</u><br/>35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(iii)  the Division of Substance Abuse and Mental Health within the Department of</u><br/>36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Human Services; or</u><br/>37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(iv)  a local substance abuse authority, as defined in Section <a href="http://le.utah.gov/UtahCode/SectionLookup.jsp?section=62a-15-102&session=2016GS">62A-15-102</a>;</u><br/>38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  a nongovernment entity, including:</u><br/>39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  a nonprofit organization; or</u><br/>40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  a for-profit organization; or</u><br/>41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  any other entity that complies with Subsections (2) and (3).</u><br/>42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  An entity operating a syringe exchange program in the state shall:</u><br/>43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  facilitate the exchange of an individual's used syringe for one or more new syringes</u><br/>44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>in sealed sterile packages;</u><br/>45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  ensure that a recipient of a new syringe is given verbal and written instruction on:</u><br/>46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  methods for preventing the transmission of blood-borne diseases, including hepatitis</u><br/>47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>C and human immunodeficiency virus; and</u><br/>48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  options for obtaining:</u><br/>49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(A)  services for the treatment of a substance use disorder;</u><br/>50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(B)  testing for a blood-borne disease; and</u><br/>51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(C)  an opiate antagonist under Chapter 55, Emergency Administration of Opiate</u><br/>52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Antagonist Act; and</u><br/>53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  report annually to the department the following information about the program's</u><br/>54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>activities:</u><br/>55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  the number of individuals who have exchanged syringes;</u><br/>56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  the number of used syringes exchanged for new syringes; and</u><br/>57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(iii)  the number of new syringes provided in exchange for used syringes.</u><br/>58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  No later than October 1, 2017, and every two years thereafter, the department shall</u><br/><hr>59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>report to the Legislature's Health and Human Services Interim Committee on:</u><br/>60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  the activities and outcomes of syringe programs operating in the state, including:</u><br/>61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  the number of individuals who have exchanged syringes;</u><br/>62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  the number of used syringes exchanged for new syringes;</u><br/>63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(iii)  the number of new syringes provided in exchange for used syringes;</u><br/>64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(iv)  the impact of the programs on blood-borne infection rates; and</u><br/>65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(v)  the impact of the programs on the number of individuals receiving treatment for a</u><br/>66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>substance use disorder;</u><br/>67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  the potential for additional reductions in the number of syringes contaminated with</u><br/>68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>blood-borne disease if the programs receive additional funding;</u><br/>69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  the potential for additional reductions in state and local government spending if the</u><br/>70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>programs receive additional funding;</u><br/>71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  whether the programs promote illicit use of drugs; and</u><br/>72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  whether the programs should be continued, continued with modifications, or</u><br/>73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>terminated.</u><br/>74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  The department shall make rules, in accordance with Title 63G, Chapter 3, Utah</u><br/>75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Administrative Rulemaking Act, specifying how and when an entity operating a syringe</u><br/>76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exchange program shall make the report required by Subsection (2)(c).</u><br/><br/><hr style="width:90%; color: #333; text-align: right" /><br/><hr style="width:90%; color: #333; text-align: right" /><br/><br/><b>Legislative Review Note<br/>Office of Legislative Research and General Counsel</b>
</font>
</div>
</body>
</html>
